UY25234A1 - Formulación de liberación prolongada de venlafaxina - Google Patents

Formulación de liberación prolongada de venlafaxina

Info

Publication number
UY25234A1
UY25234A1 UY25234A UY25234A UY25234A1 UY 25234 A1 UY25234 A1 UY 25234A1 UY 25234 A UY25234 A UY 25234A UY 25234 A UY25234 A UY 25234A UY 25234 A1 UY25234 A1 UY 25234A1
Authority
UY
Uruguay
Prior art keywords
venlafaxine
prolonged release
release formulation
tablets
venlafaxine hydrochloride
Prior art date
Application number
UY25234A
Other languages
English (en)
Inventor
Sherman Clark Amer
John Clifton Clark
John Ulrick Lamer
Sherman
Stephen Andrew White
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25508423&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY25234(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of UY25234A1 publication Critical patent/UY25234A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona con una fórmula posológica y dosis unitaria de la misma, de clorihidrato de venlafaxina, un agente antidepresivo, de liberación prolongada sobre las 24 horas, que ofrece un control mejor de las concentraciones plasmáticas que el de las fórmulas convencionales en tabletas que deben administrarse dos o más veces al día, y que también se asocia con una incidencia menor de náuseas y vómitos que las tabletas convencionales. En su aspecto primario, esta invención ofrece un núcleo mejorado de los esferoides de liberación prolongada, que comprende clorhidrato de venlafaxina y celulosa microcristalina, es decir, sin el agregado de hidroxipropilmetilcelulosa.
UY25234A 1997-11-05 1998-11-05 Formulación de liberación prolongada de venlafaxina UY25234A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96432897A 1997-11-05 1997-11-05

Publications (1)

Publication Number Publication Date
UY25234A1 true UY25234A1 (es) 2000-12-29

Family

ID=25508423

Family Applications (2)

Application Number Title Priority Date Filing Date
UY25234A UY25234A1 (es) 1997-11-05 1998-11-05 Formulación de liberación prolongada de venlafaxina
UY25692A UY25692A1 (es) 1997-11-05 1999-09-03 Método para preparar una fórmula de liberación prolongada

Family Applications After (1)

Application Number Title Priority Date Filing Date
UY25692A UY25692A1 (es) 1997-11-05 1999-09-03 Método para preparar una fórmula de liberación prolongada

Country Status (39)

Country Link
EP (1) EP1028718B1 (es)
JP (1) JP2001521892A (es)
KR (1) KR20010031797A (es)
CN (1) CN1278165A (es)
AR (1) AR014012A1 (es)
AT (1) ATE237320T1 (es)
AU (1) AU747978B2 (es)
BG (1) BG104397A (es)
BR (1) BR9813179A (es)
CA (1) CA2305242A1 (es)
CL (1) CL2004001705A1 (es)
CO (1) CO5011060A1 (es)
CZ (1) CZ20001659A3 (es)
DE (1) DE69813602T2 (es)
DK (1) DK1028718T3 (es)
EA (1) EA200000487A1 (es)
EE (1) EE04577B1 (es)
ES (1) ES2196620T3 (es)
GE (1) GEP20043198B (es)
HK (1) HK1029056A1 (es)
HR (1) HRP20000213B1 (es)
HU (1) HU225238B1 (es)
ID (1) ID26317A (es)
IL (1) IL135457A0 (es)
MA (1) MA24691A1 (es)
NO (1) NO20002126L (es)
NZ (1) NZ504460A (es)
PA (1) PA8462501A1 (es)
PE (1) PE128699A1 (es)
PL (1) PL341141A1 (es)
PT (1) PT1028718E (es)
SK (1) SK6472000A3 (es)
SV (1) SV1998000131A (es)
TR (1) TR200001232T2 (es)
TW (1) TW555568B (es)
UA (1) UA77145C2 (es)
UY (2) UY25234A1 (es)
WO (1) WO1999022724A2 (es)
ZA (1) ZA9810081B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1466889T3 (da) * 1999-04-06 2008-09-08 Sepracor Inc O-Desmethylvenlafaxin-succinat
DZ3256A1 (fr) * 1999-05-20 2000-11-30 Elan Corp Plc Preparations d'inhibiteurs specifiques du recaptage de la serotonine a liberation multiparticulaire regulee
IL146462A (en) * 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
TW200301101A (en) * 2001-12-05 2003-07-01 Wyeth Corp Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
WO2003050074A1 (en) * 2001-12-13 2003-06-19 Cadila Healthcare Limited Manufacture of venlafaxine hydrochloride and crystalline polymorphs thereof
WO2003055475A1 (en) * 2002-01-03 2003-07-10 Lek Pharmaceutical And Chemical Company D.D. Controlled release pharmaceutical formulation containing venlafaxine
AU2003219117A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Extended release venlafaxine formulations
US6696496B2 (en) 2002-03-28 2004-02-24 Synthon Bv Low water-soluble venlafaxine salts
US6717015B2 (en) 2002-03-28 2004-04-06 Synthon Bv Venlafaxine besylate
WO2003082262A2 (en) * 2002-03-28 2003-10-09 Synthon B.V. Compositions of venlafaxine base
FR2845289B1 (fr) 2002-10-04 2004-12-03 Ethypharm Sa Spheroides, procede de preparation et compositions pharmaceutiques.
CA2415154C (en) * 2002-12-24 2009-06-16 Biovail Laboratories Inc. Modified release formulations of selective serotonin re-uptake inhibitors
DE10350194B4 (de) * 2003-10-28 2005-11-10 Bioplanta Arzneimittel Gmbh Verwendung von Extrakten aus Opuntien zur Behandlung von depressiven Verstimmungen und Erkrankungen
TW200503670A (en) * 2003-03-28 2005-02-01 Sandoz Ag Venlafaxine compositions
EP1502587B1 (en) * 2003-07-30 2006-08-23 Pharmathen S.A. Sustained release formulation for Venlafaxine hydrochloride
HUP0303382A2 (hu) * 2003-10-10 2005-08-29 EGIS Gyógyszergyár Rt. Venlafaxin-hidroklorid-tartalmú pelletek
WO2005074895A1 (en) 2004-02-04 2005-08-18 Alembic Limited Extended release coated microtablets of venlafaxine hydrochloride
US7776358B2 (en) 2004-07-22 2010-08-17 Synthon Ip Inc. Extended release venlafaxine besylate tablets
CN101453996B (zh) * 2006-04-03 2016-05-11 伊萨·奥迪迪 药物递送组合物
WO2007129329A2 (en) * 2006-05-08 2007-11-15 Jubilant Organosys Limited Extended release pharmaceutical formulation comprising venlafaxine hydrochloride
CN102772390B (zh) * 2012-08-16 2014-01-08 乐普药业股份有限公司 一种盐酸文拉法辛缓释胶囊及其制备方法
FR3080278B1 (fr) * 2018-04-11 2021-04-30 Ghs Patents Ltd Procede de fabrication d'un spheroide de cannabidiol

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1561204A (en) * 1977-06-01 1980-02-13 Ici Ltd Sustained release pharmaceutical composition
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
ZA97976B (en) * 1996-04-05 1997-08-18 Alza Corp Uniform drug delivery theraphy.

Also Published As

Publication number Publication date
ES2196620T3 (es) 2003-12-16
CL2004001705A1 (es) 2005-06-03
EE04577B1 (et) 2006-02-15
GEP20043198B (en) 2004-03-25
AR014012A1 (es) 2001-01-31
TR200001232T2 (tr) 2000-12-21
HU225238B1 (en) 2006-08-28
EE200000212A (et) 2001-04-16
PE128699A1 (es) 2000-01-06
CZ20001659A3 (cs) 2001-10-17
NO20002126D0 (no) 2000-04-26
PA8462501A1 (es) 2000-05-24
CO5011060A1 (es) 2001-02-28
BG104397A (en) 2001-02-28
DE69813602D1 (de) 2003-05-22
WO1999022724A3 (en) 1999-07-22
SK6472000A3 (en) 2000-11-07
HRP20000213B1 (en) 2004-04-30
AU747978B2 (en) 2002-05-30
CN1278165A (zh) 2000-12-27
BR9813179A (pt) 2000-08-22
NO20002126L (no) 2000-05-04
HUP0004287A3 (en) 2002-05-28
HRP20000213A2 (en) 2000-12-31
PT1028718E (pt) 2003-07-31
EP1028718B1 (en) 2003-04-16
UY25692A1 (es) 2000-03-31
KR20010031797A (ko) 2001-04-16
MA24691A1 (fr) 1999-07-01
PL341141A1 (en) 2001-03-26
DK1028718T3 (da) 2003-07-28
HUP0004287A2 (hu) 2002-04-29
IL135457A0 (en) 2001-05-20
TW555568B (en) 2003-10-01
SV1998000131A (es) 1999-11-18
EA200000487A1 (ru) 2000-10-30
ID26317A (id) 2000-12-14
NZ504460A (en) 2003-01-31
EP1028718A2 (en) 2000-08-23
WO1999022724A2 (en) 1999-05-14
JP2001521892A (ja) 2001-11-13
ZA9810081B (en) 2000-05-04
AU1300399A (en) 1999-05-24
UA77145C2 (en) 2006-11-15
DE69813602T2 (de) 2003-11-06
ATE237320T1 (de) 2003-05-15
CA2305242A1 (en) 1999-05-14
HK1029056A1 (en) 2001-03-23

Similar Documents

Publication Publication Date Title
UY25234A1 (es) Formulación de liberación prolongada de venlafaxina
AR006519A1 (es) Formula encapsulada de liberacion prolongada de clorhidrato de venlafaxina, una formula de pelicula de recubrimiento, y el uso de dicha formula encapsuladapara preparar una formulacion de liberacion prolongada
MY142403A (en) Oral dosage forms for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient
MX2007006212A (es) Medicamento oral para liberacion modificada de al menos un principio activo bajo forma multimicrocapsular.
ECSP045102A (es) Formulación farmacéutica que contiene 3-(3-dimetilamino-1-etil-2-metil-propil)fenol y proporciona una liberación retardada del ingrediente activo
NO20052479L (no) Tramadolformuleringer med forsinket frigjoring og 24 timers effektivitet
ES2530719T3 (es) Formulaciones de oxicodona para ser administradas una vez al día
ID27504A (id) Formulasi oral baru
SE9704869D0 (sv) New pharmaceutical formulaton II
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
NZ509028A (en) Stable extended release oral dosage composition comprising a pseudoephedrine-containing core, the core being uniformly covered with a desloratadine-containing film
SV1999000148A (es) Desnaturalizantes para las sales aminas simpaticomimeticas
ATE460157T1 (de) Pharmazeutische metformintablette mit verlängerter freisetzung
ES2191987T3 (es) Formas de dosificacion de ribavirina solidas, administrables oralmente, y procedimiento de fabricacion.
BR0211198A (pt) Composições farmacêuticas e seu uso
RS50298B (sr) Direktno kompresibilna matrica za kontrolisano oslobađanje pojedinačnih dnevnih doza klaritromicina
ES2305567T3 (es) Formulaciones de tramadol de liberacion sostenida con una eficacia de 24 horas.
TR200200978T2 (tr) Yeni mirtazapin formülasyonu
AR014082A1 (es) Concentrado oral de sertralina
ECSP982704A (es) Formula de liberacion prolongada
ECSP972046A (es) Formula de liberacion prolongada
WO2003105811A8 (en) PROGRESSIVE RELEASE COMPOSITIONS AND METHOD OF USE
DK0483320T3 (da) Farmaceutiske sammensætninger med forlænget frigivelse til peroral indgivelse og fremgangsmåde til fremstilling deraf
AR034505A1 (es) Composiciones medicinales y proceso de manufactura
DE60112578D1 (de) Pharmazeutische diclofenac-verbindung basierend auf vitamin e, papain und hyaluronidase

Legal Events

Date Code Title Description
VENC Patent expired

Effective date: 20181105